75
Participants
Start Date
March 31, 2011
Primary Completion Date
August 31, 2016
Study Completion Date
January 31, 2017
MM-302 Monotherapy
Escalating doses of MM-302 as a single agent
MM-302 in combination with trastuzumab
Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule
MM-302 in combination with trastuzumab q3w
Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule
MM-302 in combination with trastuzumab and cyclophosphamide
Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
University of California San Francisco, San Francisco
University of Indiana, Indianapolis
Dana Farber Cancer Center, Boston
Karmanos Cancer Center, Detroit
Washington University, St Louis
Lead Sponsor
Merrimack Pharmaceuticals
INDUSTRY